270 results match your criteria: "France Centre Mémoire de Ressources et de Recherche[Affiliation]"
Ann Epidemiol
January 2025
University of California, Los Angeles Fielding School of Public Health Department of Epidemiology, Los Angeles, CA, USA. Electronic address:
Purpose: Harmonizing variables for constructs measured differently across studies is essential for comparing, combining, and generalizing results. We developed and fielded a brief survey to harmonize Likert and continuous versions of measures for two constructs, self-rated health and self-rated memory, for use in studies of French older adults.
Methods: We recruited 300 participants from a French memory clinic in 2023 to answer both the Likert and continuous versions of self-rated health and self-rated memory questions.
J Neurol
December 2024
Service de Médecine Interne, Centre de Référence Des Maladies Héréditaires du Métabolisme, UMR INSERM 1253 « iBraiN », Université de Tours, CHU de Tours, Tours, France.
Background And Objective: Adult patients with early-treated phenylketonuria (AwET-PKU) may present some subtle neurocognitive deficits. The aim of the study was to investigate 1) neurocognitive functions in a large group of AwET-PKU 2) the influence of plasma phenylalanine (Phe).
Methods: Participants: 187 AwET-PKU (classic PKU [cPKU] 81%, mild PKU [mPKU] 14%, and mild persistent hyperphenylalaninemia [MPH] 5%).
Front Digit Health
November 2024
Department of Circuit Theory, Czech Technical University in Prague, Prague, Czechia.
[This corrects the article DOI: 10.3389/fdgth.2024.
View Article and Find Full Text PDFBMC Psychiatry
November 2024
Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen University, Aachen, Germany.
Background: Psychiatry faces a challenge due to the lack of objective biomarkers, as current assessments are based on subjective evaluations. Automated speech analysis shows promise in detecting symptom severity in depressed patients. This project aimed to identify discriminating speech features between patients with major depressive disorder (MDD) and healthy controls (HCs) by examining associations with symptom severity measures.
View Article and Find Full Text PDFJAMA Neurol
December 2024
Laboratory of Neuroimaging of Aging, University of Geneva, Geneva, Switzerland.
Alzheimers Res Ther
October 2024
Univ. Bordeaux, Bordeaux Population Health, UMR1219, Inserm, Bordeaux, France.
Alzheimers Dement (Amst)
October 2024
German Center for Neurodegenerative Diseases (DZNE), Rostock Greifswald Germany.
Seizure
September 2024
Centre Mémoire, de Ressources et de Recherche de Strasbourg, France; Unité de Neuropsychologie, Service de Neurologie des Hôpitaux Universitaires de Strasbourg, Strasbourg, France; University of Strasbourg and CNRS, ICube laboratory UMR 7357 and FMTS (Fédération de Médecine Translationnelle de Strasbourg), team IMIS/Neurocrypto Strasbourg, France; Centre de Compétences des démences rares des Hôpitaux Universitaires de Strasbourg, France. Electronic address:
Child Adolesc Psychiatry Ment Health
September 2024
Inserm U1094, IRD UMR270, Univ. Limoges, CHU Limoges, EpiMact- Epidemiology of chronic diseases in tropical zone, Institute of Epidemiology and Tropical Neurology, OmegaHealth, Limoges, France.
Background: In 2019, the world faced a pandemic brought about by a severe acute respiratory infection caused by SARS-CoV-2 virus. The spread of this virus has profoundly affected societies, particularly in terms of their economic, human and social dimensions, as well as their healthcare systems. Several restrictive measures (reduced social interaction, periodic school closures,…) had to be taken to contain the spread of the virus.
View Article and Find Full Text PDFSoins Gerontol
September 2024
Service Gériatrie 1&2, Centre Mémoire de Ressources et de Recherche d'Île-de-France Sud-Site Broca, AP-HP, Hôpital Broca, 54-56 rue Pascal, 75013 Paris, France; Université Paris Cité, Maladie d'Alzheimer, 54-56 rue Pascal, 75013 Paris, France. Electronic address:
High-risk drugs, which are potentially a source of serious adverse reactions, are a major concern in healthcare establishments, particularly for geriatric patients, who often have multiple medications and co-morbid conditions. With a view to continuously improving the quality and safety of care, we have embarked on a proactive approach aimed at identifying, securing and improving the management of medicines at risk in geriatric wards.
View Article and Find Full Text PDFGeroscience
August 2024
ICube Laboratory UMR 7357 and FMTS (Fédération de Médecine Translationnelle de Strasbourg), IMIS (Imagerie Multimodale Intégrative en Santé) Team and IRIS Platform, University of Strasbourg and CNRS (Centre National de La Recherche Scientifique, National Center of Scientific Research), 4 Rue Kirschleger, 67000, Strasbourg, France.
Identifying and validating a biomarker with high specificity in early-stage dementia with Lewy bodies (DLB) using a feasible method is crucial to enhance the current suboptimal diagnostic procedure. Previous research revealed abnormalities, including hypoperfusion in the right anterior insular cortex at group level, in prodromal DLB. Exploring hypoperfusion of the right anterior insula, at an individual-level and assessing its relevance as a potential imaging biomarker in early DLB, has, to our knowledge, not been investigated.
View Article and Find Full Text PDFFront Digit Health
July 2024
Department of Circuit Theory, Czech Technical University in Prague, Prague, Czechia.
Introduction: Dysarthria, a motor speech disorder caused by muscle weakness or paralysis, severely impacts speech intelligibility and quality of life. The condition is prevalent in motor speech disorders such as Parkinson's disease (PD), atypical parkinsonism such as progressive supranuclear palsy (PSP), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS). Improving intelligibility is not only an outcome that matters to patients but can also play a critical role as an endpoint in clinical research and drug development.
View Article and Find Full Text PDFNeurophysiol Clin
September 2024
Univ. Lille, INSERM, U1172 - LilNCog - Lille Neuroscience & Cognition, F-59000 Lille, France. Electronic address:
This study aimed to compare the diagnostic performance of visual assessment of electroencephalography (EEG) using the Grand Total EEG (GTE) score and quantitative EEG (QEEG) using spectral analysis in the context of cognitive impairment. This was a retrospective study of patients with mild cognitive impairment, with (MCI+V) or without (MCI) vascular dysfunction, and patients with dementia including Alzheimer's disease, Lewy Body Dementia and vascular dementia. The results showed that the GTE is a simple scoring system with some potential applications, but limited ability to distinguish between dementia subtypes, while spectral analysis appeared to be a powerful tool, but its clinical development requires the use of artificial intelligence tools.
View Article and Find Full Text PDFNeurodegener Dis
July 2024
CoBTeK Laboratory, Université Cote d'Azur, Nice, France.
Introduction: Remote digital assessments (RDAs) such as voice recording, video and motor sensors, olfactory, hearing, and vision screenings are now starting to be employed to complement classical biomarker and clinical evidence to identify patients in the early AD stages. Choosing which RDA can be proposed to individual patients is not trivial and often time-consuming. This position paper presents a decision-making algorithm for using RDA during teleconsultations in memory clinic settings.
View Article and Find Full Text PDFEur J Epidemiol
May 2024
CNRS, UMR 5525, VetAgro Sup, Grenoble INP, CHU Grenoble Alpes, TIMC, Univ. Grenoble Alpes, Grenoble, 38000, France.
J Neural Transm (Vienna)
July 2024
Department of Clinical Pharmacology and Neurosciences, Clinical Investigation Center CIC1436, Toulouse Parkinson Expert Centre, Toulouse NeuroToul Center of Excellence in Neurodegeneration (COEN), University of Toulouse 3, CHU of Toulouse, INSERM, Toulouse, France.
Neurology
April 2024
From the Univ. Bordeaux (V.B., G.C., C.D.), Inserm, Bordeaux Population Health, UMR1219, Bordeaux; CIC 1401 EC (V.B., G.C., C.D.), Pôle Santé Publique, CHU de Bordeaux; Laboratory of Immunology and Immunogenetics (I.P.), Resources Biological Center (CRB), CHU Bordeaux; Univ. Bordeaux (I.P.), CNRS, ImmunoConcEpT, UMR 5164, Bordeaux; Alzheimer Research Center IM2A (B.D.), Salpêtrière Hospital, AP-HP, Sorbonne University, Paris; Univ. Bordeaux (V.P.), CNRS, Institut des Maladies Neuroégénératives, UMR 5293, Bordeaux; Pôle de Neurosciences Cliniques (V.P.), Centre Mémoire de Ressources et de Recherche, CHU Bordeaux, France.
Background And Objectives: Patients' comorbidities can affect Alzheimer disease (AD) blood biomarker concentrations. Because a limited number of factors have been explored to date, our aim was to assess the proportion of the variance in fluid biomarker levels explained by the clinical features of AD and by a large number of non-AD-related factors.
Methods: MEMENTO enrolled 2,323 individuals with cognitive complaints or mild cognitive impairment in 26 French memory clinics.
Rev Prat
December 2023
CHU de Rennes, service de neurologie, centre mémoire de ressources et de recherche, Rennes ; Inria, CNRS, Inserm, IRISA UMR 6074, Empenn U1228, université de Rennes, Rennes, France.
MANAGEMENT OF AN AMNESIC PATIENT. Until the early 1980s, neuropsychological rehabilitation of amnesic syndromes was limited to extensive repeated practice ('cognitive drill'). The ineffectiveness of these methods is now acknowledged, if the therapeutic target concerns daily life.
View Article and Find Full Text PDFRev Prat
December 2023
Centre mémoire de ressources et de recherche (CMRR) de Strasbourg-Colmar, France. Pôle de gérontologie, Hôpitaux civils de Colmar, Colmar, France.
Genet Med
May 2024
Univ Rouen Normandie, Normandie Univ, Inserm U1245 and CHU Rouen, Department of Neurology and CNRMAJ, F-76000 Rouen, France.
Purpose: To assess the likely pathogenic/pathogenic (LP/P) variants rates in Mendelian dementia genes and the moderate-to-strong risk factors rates in patients with Alzheimer disease (AD).
Methods: We included 700 patients in a prospective study and performed exome sequencing. A panel of 28 Mendelian and 6 risk-factor genes was interpreted and returned to patients.
Eur J Epidemiol
March 2024
CNRS, UMR 5525, VetAgro Sup, Grenoble INP, CHU Grenoble Alpes, TIMC, Univ. Grenoble Alpes, 38000, Grenoble, France.
Data regarding Alzheimer's disease (AD) occurrence in farming populations is lacking. This study aimed to investigate whether, among the entire French farm manager (FM) workforce, certain agricultural activities are more strongly associated with AD than others, using nationwide data from the TRACTOR (Tracking and monitoring occupational risks in agriculture) project. Administrative health insurance data (digital electronic health/medical records and insurance claims) for the entire French agricultural workforce, over the period 2002-2016, on the entire mainland France were used to estimate the risk of AD for 26 agricultural activities with Cox proportional hazards model.
View Article and Find Full Text PDFAlzheimers Dement
March 2024
Univ. Bordeaux, CNRS, Institut des Maladies Neurodégénératives, Bordeaux, France.
Introduction: The "prion-like" features of Alzheimer's disease (AD) tauopathy and its relationship with amyloid-β (Aβ) have never been experimentally studied in primates phylogenetically close to humans.
Methods: We injected 17 macaques in the entorhinal cortex with nanograms of seeding-competent tau aggregates purified from AD brains or control extracts from aged-matched healthy brains, with or without intracerebroventricular co-injections of oligomeric-Aβ.
Results: Pathological tau injection increased cerebrospinal fluid (CSF) p-tau181 concentration after 18 months.
Geriatr Psychol Neuropsychiatr Vieil
September 2023
CMRR Toulouse, Gérontopôle de Toulouse, CHU Toulouse, UMR Inserm 1295 Cerpop, IHU HealthAge.
New ministerial decree restricts driving motorized vehicles for patients with Alzheimer's disease and related disorders. Reisberg stage 3, threshold used to contraindicate driving, appears to correspond to a mild stage of major neurocognitive impairment. A single scale gives an idea of the level of risk but does not provide a holistic assessment.
View Article and Find Full Text PDFGeriatr Psychol Neuropsychiatr Vieil
September 2023
EA 4468, Université Paris Cité, Maladie d'Alzheimer, Paris, France, Consultation mémoire/Accueil de jour, Ccentre Hospitalier des Quatre Villes, Sèvres, Saint-Cloud, France, Institut d'Enseignement à Distance, Université Paris 8, Saint-Denis, France.
The publication of the decree on the care of people with neurocognitive disorders brought to the fore the Reisberg's Global Deterioration Scale, a scale that only few clinicians use in memory centers or in geriatric. This scale has a number of limitations, not least of which is that it is obsolete, since it does not take into account disease advances in scientific knowledge with biomarkers. Consequently, the stages evoked no longer correspond to current descriptions.
View Article and Find Full Text PDFAlzheimers Res Ther
November 2023
UMR 1219, Bordeaux Population Health Center, University of Bordeaux, Inserm, Bordeaux, F-33000, France.
Background: Cognitive complaints are often regarded as an early sign of Alzheimer's disease (AD) but may also occur in several other conditions and contexts. This study examines the correlates of cognitive complaint trajectories over a 5-year period in individuals who shared similar objective cognitive trajectories.
Methods: We analyzed a subsample (n = 1748) of the MEMENTO cohort, consisting of individuals with subjective cognitive decline or mild cognitive impairment at baseline.